- authorisedHuman Pharmacology (Phase I)- First administration to humans
First-in-Human Trial of DS1025a in Participants with Advanced Solid Tumors
This clinical trial tests a new drug called DS1025a in humans for the first time. It is for adults with advanced solid tumours that cannot be removed by surgery or have spread. Researchers want to find out if the drug is safe, learn its side effects, and find the right dose.
France - recruitingPHASE1, PHASE2
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
This study is testing a new drug, zidesamtinib, for people with advanced cancer that has a specific genetic change called a ROS1 rearrangement. It will check how safe the drug is and if it can shrink tumours.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
This study is testing a new drug, neladalkib, for advanced cancers that have a specific genetic change called ALK rearrangement. It's looking at how safe the drug is and if it shrinks tumours in people with certain types of lung cancer and other solid tumours.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This study is testing a new drug, ART6043, alone or with an existing drug, olaparib, for people with advanced or metastatic solid tumours. Researchers want to see if it's safe, how it works in the body, and if it helps treat these cancers, especially those with certain genetic changes.
United States · Spain · United Kingdom - recruitingPHASE1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.
United States · Australia · China - recruitingPHASE1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
This study looks at a new drug, LY4050784, for advanced or metastatic solid cancers. We want to see if it's safe and effective, on its own or with other medicines, especially for cancers with a specific gene change called SMARCA4 (BRG1).
United States · France · Germany - recruitingPHASE1, PHASE2
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
This study is testing a new drug, IPN01203, for adults with advanced cancers that have spread. We're looking at its safety, best dose, and how well it works, especially for those who've had previous treatments. It's hoped to help control cancer growth.
United States · Canada · France - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE1, PHASE2
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
This study is testing a new injection, IP-001, after a heat treatment called thermal ablation for certain advanced cancers (bowel, lung, soft tissue sarcoma) that haven't responded to previous treatments. It aims to see if it's safe and effective, potentially offering a new treatment option.
United States · France · Germany - recruitingPHASE1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.
United States · Spain · United Kingdom